!

COVID-19 Response

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Healthcare: Cancer Care

Mesothelioma

Master
Media Component
Baylor College of Medicine
Media
Credit
Heading

Multidisciplinary Team and Personalized Treatment

Content

The Mesothelioma Treatment Center located at the Baylor Medicine Lung Institute is recognized worldwide, as a leading-edge center for the diagnosis, treatment, and research of malignant mesothelioma.

Our multidisciplinary team of surgeons, oncologists, radiologists, pathologists, and intensivists specifically tailor for you a comprehensive personalized treatment plan that will target your disease. With our cutting-edge clinical, biomedical, and basic research programs, we strive to integrate the most innovative and up-to-date understanding of mesothelioma into your treatment plan. In addition, our medical staff together with the members of our support program, including our social workers, case managers, and spiritual guides, will make every effort to address any special need you may have and will make sure that you and your family are involved and comfortable with every step of your diagnosis, treatment, and follow-up.

Heading

Mesothelioma Treatment Goals

Content

Mesothelioma is an aggressive asbestos-related malignancy that originates from the cells (mesothelial cells) that compose the thin tissue (serosa) that lines the walls and organs of the lungs and abdomen.

Although mesothelioma typically has a dire prognosis, physicians and researchers at the Mesothelioma Treatment Center are coming up with increasingly sophisticated ways to diagnose and treat this disease.

Treatment at the Mesothelioma Treatment Center is often multimodal and typically involves surgery to remove any tumor visible to the naked eye in combination with chemotherapy and/or radiation and/or immunotherapy. Members of our team have refined surgical techniques and incorporated new treatment modalities to improve outcomes for mesothelioma patients.

Heading

Personalized Genetic and Immune Based Therapies

Content

When you are evaluated at the Mesothelioma Treatment Center, tissues from your tumor and blood will be analyzed for the expression of distinct genes and immune markers to comprehensively evaluate what specific therapies would work better in your case.

Our panel of markers and clinical trials is expanding at a steady pace and will provide you with access to the most advanced treatment options available.

Heading

Facts About Mesothelioma

Content

Malignant mesothelioma is a type of cancer that affects the cells of the mesothelium.

What is the mesothelium?

The mesothelium is a membrane that lines and protects organs in the chest and in the abdominal cavity. The mesothelium has different names depending on the organs it surrounds:

  • The pleura lines the lungs.
  • The peritoneum surrounds the organs within the abdominal cavity.
  • The pericardium envelops the heart.
  • The tunica vaginalis coats the testicles.

Malignant pleural mesothelioma is a malignant or cancerous tumor of the pleura, the mesothelium that surrounds the lungs. About two of every three mesothelioma cases are pleural mesothelioma. Most of the remaining cases are mesotheliomas of the peritoneum surrounding organs in the abdominal cavity. Mesotheliomas of the membranes that surround the heart or the testicles are very rare.

MPM affects over 2,000 people a year in the U.S.; before 2030, an estimated 300,000 cases will be diagnosed. Epidemiological studies predict that approximately 250,000 Europeans will develop mesothelioma in the next few decades.

As the malignant cells grow, the pleura thickens and presses on the lungs. These changes in the pleura can make breathing difficult. Without treatment, most patients will die from mesothelioma within 4 to 12 months from the time of diagnosis. The most common causes of death are respiratory failure or pneumonia. In about one of every three patients, a small bowel obstruction develops as a result of direct extension of tumor through the diaphragm. About 1 in 10 patients die of cardiac complications when the tumor invades the pericardium and the heart.

Heading

Subtypes of MPM and Prognosis

Content

Three subtypes of mesothelioma have been identified according to microscopic appearance:

  • Epithelial - associated with the best prognosis or outcome
  • Sarcomatoid
  • Mixed types
Content

Other factors that may predict a favorable outcome are:

  • Younger age
  • Good performance status
  • Early-stage disease
  • Lack of chest pain at diagnosis
Heading

Risk Factors

Content

Asbestos. Asbestos is a heat-resistant mineral used in fire-resistant and insulating materials. Exposure to asbestos is the highest risk factor for developing MPM. Between 50 percent and 80 percent of patients diagnosed with MPM are aware of exposure to asbestos at some point in their lives.

MPH affects more men than women. This is probably because more men work in industrial settings in which asbestos is common presence. The increasing incidence suggests either that the benefits of legislation to reduce asbestos exposure in the workplace have not yet taken effect, or that asbestos exposure during the 1960s was more widespread than previously believed.

Radiation. Radiation is another risk factor associated with MPM. Radiation-induced malignant mesothelioma appears to have the same prognosis as asbestos-related mesothelioma.

Genetic Factors. A significant percentage of mesothelioma patients have not been exposed to asbestos. This has led some experts to argue for a genetic predisposition. The fact that only about 5 percent of South African asbestos mine workers developed mesothelioma suggests that other environmental or genetic factors are involved.

SV-40 Virus. In addition to asbestos, some researchers have implicated exposure to the SV-40 virus, which is known to have contaminated some polio vaccines, as potentially related to this malignancy, but this has not been proven.